Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxyphenbutazone Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxyphenbutazone Anhydrous SCHEMBL5316370 | 1.00 | LMNA (1.00) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL11337449 | 1.00 | LMNA (1.00) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL25857 | 1.00 | LMNA (1.00) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL3182776 | 0.99 | LMNA (0.97) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL1263248 | 0.99 | LMNA (0.97) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL2525061 | 0.99 | LMNA (0.97) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL25854 | 0.99 | LMNA (0.97) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL1263243 | 0.97 | LMNA (0.94) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL28278628 | 0.97 | LMNA (0.94) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL9753930 | 0.96 | LMNA (0.92) | LMNARAB9AALDH1A1CYP3A4PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 26373 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-20260130928-A1 | COMBINATION OF AKR1C3 ACTIVATED ANTICANCER PRODRUG COMPOUND AND ANALGESIC DRUG FOR TREATING CANCER PATIENTS ACCOMPANIED BY PAIN | ASCENTAWITS PHARMACEUTICALS LTD (CN) | 2026-05-14 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4714928-A1 | A REACTIVE RESIN COMPOSITION COMPRISING A PEROXIDE-FREE INITIATOR SYSTEM WITH A HETEROCYCLIC COMPOUND COMPRISING AT LEAST ONE N-N SINGLE BOND | Hilti Aktiengesellschaft (LI) | 2026-03-25 | — | — | EP | claimed |
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ACERAGEN INC (US) | 2026-01-01 | — | — | US | claimed |
| WO-2025199660-A1 | THIONOCARBAMATE- AND LIGNIN-COLLECTING COMPOSITIONS | Oxiquim S.A. (CL) | 2025-10-02 | — | — | WO | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12364703-B2 | Homogeneous ophthalmic composition | ADCOX, JAMES M., III | 2025-07-22 | — | — | US | claimed |
| WO-2025132620-A1 | STABLE SOFT CAPSULE PREPARATIONS WITH SOLID FILL FOR MOISTURE SENSITIVE ACTIVE INGREDIENTS | BAYER CONSUMER CARE AG (CH) | 2025-06-26 | — | — | WO | claimed |
| EP-4561631-A2 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | Alnylam Pharmaceuticals, Inc. (US) | 2025-06-04 | — | — | EP | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| US-4478822-A | Drug delivery system utilizing thermosetting gels | MERCK & CO., INC. (US) | 1984-10-23 | — | — | US | claimed |
| US-4474752-A | DIAMINE MODIFIED POLYOXYETHYLENE-POLYOXYPROPYLENE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |
| EP-0010061-B1 | PHARMACEUTICAL PREPARATIONS CONTAINING A MOLLUSC EXTRACT | Mc Farlane, Stuart John (NZ) | 1983-07-13 | — | — | EP | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| US-4216212-A | Pyrazolidine anti-inflammatory composition and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 1980-08-05 | — | — | US | claimed |
| WO-1980000661-A1 | PHARMACEUTICAL PREPARATIONS | CROFT J (NZ) | 1980-04-17 | — | — | WO | claimed |
| EP-0010061-A1 | Pharmaceutical preparations containing a mollusc extract | Mc Farlane, Stuart John (NZ) | 1980-04-16 | — | — | EP | claimed |
| US-4169147-A | Novel transient pro-drug forms of phenylbutazone and oxyphenbutazone in compositions and methods of use | INTERX RESEARCH CORPORATION (US) | 1979-09-25 | — | — | US | claimed |
| US-4151292-A | ANTIINFLAMMATORY SIDE EFFECT INHIBITION USING CHROMENE DERIVATIVES, GASTROINTESTINAL DISORDERS | FISONS LIMITED (GB) | 1979-04-24 | — | — | US | claimed |